SCHEMBL1035586

SCHEMBL1035586

Fc1ccc(-c2ccc3cccc(NCc4cccnc4)c3n2)cc1C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VNN1 O95497 1/20 0.48
ALDH1A1 P00352 5/20 0.46
KDM4E B2RXH2 4/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
SUCNR1 Q9BXA5 4/20 0.43
MEN1 O00255 1/20 0.43
MAPT P10636 1/20 0.43
PABPC1 P11940 1/20 0.43
KMT2A Q03164 1/20 0.43
GRIN1 Q05586 1/20 0.42
GRIN2B Q13224 1/20 0.42
CYP1A2 P05177 5/20 0.42
CYP3A4 P08684 5/20 0.42
CYP2D6 P10635 5/20 0.42
CYP2C19 P33261 5/20 0.42
CYP2C9 P11712 4/20 0.42
USP1 O94782 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1033950 0.85 CYP3A4 (0.53) VNN1ALDH1A1KDM4ELMNAHTT
SCHEMBL1204069 0.85 CYP3A4 (0.53) VNN1ALDH1A1KDM4ELMNAHTT
SCHEMBL1034303 0.82 VNN1 (0.48) VNN1ALDH1A1KDM4ELMNAHTT
SCHEMBL1031391 0.82 VNN1 (0.43) VNN1ALDH1A1KDM4ELMNAHTT
SCHEMBL1035436 0.82 P2RX7 (0.48) ALDH1A1KDM4EMEN1MAPTKMT2A
SCHEMBL1035493 0.82 KMT2A (0.50) ALDH1A1KDM4EMEN1MAPTKMT2A
SCHEMBL1033966 0.82 CYP1A2 (0.57) ALDH1A1KDM4EMEN1MAPTKMT2A
SCHEMBL1032557 0.80 CYP3A4 (0.55) ALDH1A1KDM4ELMNAMEN1KMT2A
SCHEMBL1035314 0.80 ADRA2C (0.49) ALDH1A1KDM4EMEN1MAPTKMT2A
SCHEMBL1076858 0.77 CLK4 (0.67) ALDH1A1KDM4ELMNASMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 US disclosed
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 US disclosed
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 US disclosed
EP-2273992-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS Sirtris Pharmaceuticals, Inc. (US) 2011-01-19 EP disclosed
WO-2009134973-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2009-11-05 WO disclosed
WO-2009134973-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2009-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRT3, SIRT1, SIRT2 VNN1 2303/4885ALDH1A1 2326/4885KDM4E 1791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.